Biogenvs.Incyte
BIIB vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.3× larger than Incyte by market cap; Incyte trades at the lower P/E (16.1 vs 21.3); year to date, Incyte leads (+18.2% vs +13.2%).
Side by side
| BIIB | INCY | |
|---|---|---|
| Market cap | $29.3B | $23.1B |
| Price | $199.15 | $116.71 |
| Today | +0.1% | −1.5% |
| Return YTD | +13.2% | +18.2% |
| Return 1Y | +47.2% | +65.9% |
| P/E | 21.3 | 16.1 |
| P/S | 2.9 | 4.3 |
| P/B | 1.6 | 4.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →More comparisons in Biotech & innovation
See where BIIB and INCY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →